Lymphoid or Myeloid Malignancies and Cellular Therapies – HS Clinical or Clinical X Faculty Full-time

Lymphoid or Myeloid Malignancies and Cellular Therapies – HS Clinical or Clinical X Faculty

Instructor, Assistant, Associate or Full HS Clinical or Clinical X Professor- Lymphoid or Myeloid Malignancies and Cellular Therapies

The Department of Medicine of the University of California, San Francisco and the Division of Hematology/Oncology invite applications for a full-time faculty appointment in the UCSF Hematology, Blood and Marrow Transplant and Cellular Therapies program. The candidate will have responsibility for patient care, clinical research and teaching. It is expected that the candidate will develop an independent clinical research program in the treatment of lymphoid or myeloid malignancies (e.g. Non-Hodgkin's Lymphoma, Multiple Myeloma, Acute Leukemia/Myelodysplasia) or solid tumor malignancies using novel immunotherapies which may include cellular therapeutics. Applicants must have an MD or equivalent, fellowship training in Hematology/Oncology, Stem Cell Transplantation and/or Cell Therapies and be board certified or eligible in Hematology or Medical Oncology. Applicants should also have demonstrated the ability to develop and conduct clinical research studies. The appointment will be made in the Health Sciences Clinical or Clinical X series at a rank of Clinical Instructor, Assistant, Associate, or Full Professor as compatible with the candidate's qualifications. Rank and compensation will be commensurate with experience.

Please submit a curriculum vitae, cover letter, statement of research, statement of teaching, and contact information for three references. Applicants' materials must list current and/or pending qualifications upon submission.

The posted UC salary scales set the minimum pay determined by rank and step at appointment. See Table 5. The minimum base salary range for this position is $110,500-$333,700. This position includes membership in the health sciences compensation plan which provides for eligibility for additional compensation.